Abstract library

2006 results for "gastrointestinal tumor".
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm
Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Medical Student Michala Danielle Zacho
#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Daneng Li
Authors: Li D, Imbesi G, Yen L, Kim H, ...
#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: MD Anna La Salvia
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#2805 Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT
Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Hannah Monahan
#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
Introduction: Neuroendocrine tumors (NETs) comprise
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...